Which medication wins the battle in COPD?

There is always one drugs trying to stake its place as being better than another. A new report suggests that tiotropium (Spiriva) may be “better” than a rival long-acting bronchodilator, salmetrol (Serevent), in a head-to-head comparison. What the “battle” was about was the length of time to having an exacerbation of COPD related symptoms (cough, sputum production, bronchitis, etc). The tiotropium brand had a longer time to exacerbation (187 days) than the salmetrol (145 days).

One word of caution, however, was ...

Continue Reading →

COPD and rationale usage of medications

In a GLUCOLD Study from the Neitherlands, by adding inhaled fluticasone (inhaled corticosteroid, ICS) to inhalation therapy in patients with chronic obstructive lung disease (COPD) it was demonstrated to improve “quality of life” parameters, reduce inflammation in patient’s airways (as shown by a reduction of mast cells, neutrophils and eosinophils in sputum, and reduced airways hyper-responsiveness compared to placebo at 6 months of treatment. Cessation of the fluticasone resulted in reversal of benefits back to baseline. This could mean that ...

Continue Reading →

Loss of lung function

While chatting to my patients I find it helpful to refer to the graph shown below to help educating individuals about the decline in lung function in normal patients, cigarette smokers and in those people who quit smoking.

The purpose of this graph is to visually explain what may be predicted on the basis for those individuals who qualify for one or the other categories.




Continue Reading →